Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Thomas C. K. Chan"'
Autor:
Mark A. Ashwell, Jean-Marc Lapierre, Christopher Brassard, Karen Bresciano, Cathy Bull, Susan Cornell-Kennon, Sudharshan Eathiraj, Dennis S. France, Terence Hall, Jason Hill, Eoin Kelleher, Sampada Khanapurkar, Darin Kizer, Steffi Koerner, Jeff Link, Yanbin Liu, Sapna Makhija, Magdi Moussa, Nivedita Namdev, Khanh Nguyen, Robert Nicewonger, Rocio Palma, Jeff Szwaya, Manish Tandon, Uma Uppalapati, David Vensel, Laurie P. Volak, Erika Volckova, Neil Westlund, Hui Wu, Rui-Yang Yang, Thomas C. K. Chan
Publikováno v:
Journal of Medicinal Chemistry. 55:5291-5310
This paper describes the implementation of a biochemical and biophysical screening strategy to identify and optimize small molecule Akt1 inhibitors that act through a mechanism distinct from that observed for kinase domain ATP-competitive inhibitors.
Publikováno v:
NeuroReport. 9:1441-1445
Osteogenic protein-1 (OP-1, BMP-7) is a member of the transforming growth factor-beta (TGF-beta) superfamily that selectively induces dendritic outgrowth from cultured neurons. We injected human recombinant OP-1 (1 or 10 micrograms) or vehicle into t
Autor:
Sudharshan, Eathiraj, Rocio, Palma, Marscha, Hirschi, Erika, Volckova, Enkeleda, Nakuci, Jennifer, Castro, Chang-Rung, Chen, Thomas C K, Chan, Dennis S, France, Mark A, Ashwell
Publikováno v:
The Journal of biological chemistry. 286(23)
Protein kinase inhibitors with enhanced selectivity can be designed by optimizing binding interactions with less conserved inactive conformations because such inhibitors will be less likely to compete with ATP for binding and therefore may be less im
Autor:
Thomas C. K. Chan, Raymond L. Konger
Publikováno v:
Journal of Cellular Physiology. 156:515-521
Previous studies have reported that the proliferation of A431 cells, a human squamous cell carcinoma cell line, was stimulated by picomolar epidermal growth factor (EGF) but inhibited by nanomolar EGF. This biphasic dose-response phenomenon is not ob
Autor:
Chang-Rung Chen, Jean-Marc Lapierre, Jeffrey D. Szwaya, Yanbin Liu, Nivedita Namdev, Deirdre Lowe, Ron E. Savage, Cathy O. Bull, Thomas C K Chan, Mark A. Ashwell, Dennis S. France
Publikováno v:
Cancer Research. 70:4501-4501
An activating somatic mutation in BRAF kinase (V600E) is found in approximately 70% of melanomas, 50% of papillary thyroid cancers and 10% of colon cancers, fueling interest in BRAF (V600E) as a therapeutic target for cancer treatment. We have previo
Publikováno v:
Cancer chemotherapy and pharmacology. 19(1)
While N-phosphonacetyl-L-aspartic acid (PALA), an inhibitor of de novo pyrimidine biosynthesis, demonstrated a unique spectrum of activity during preclinical drug evaluation, multiple clinical trials have shown it to possess minimal clinical activity
Autor:
Craig E. Pfeifle, Raymond Taetle, Thomas C. K. Chan, Ian Abramson, Maurie Markman, Stephen B. Howell
Publikováno v:
Cancer Chemotherapy and Pharmacology. 22
The availability of uridine can alter the sensitivity of tumor cells to antimetabolites such as N-phosphonacetyl-L-aspartic acid (PALA) and acivicin by virtue of the cell's ability to salvage preformed metabolites from its environment. We investigate